GLP-1 drugs show new benefits for heart, fertility, cancer and reveal emerging risks
Updated
Updated · South Florida Sun Sentinel · Apr 26
GLP-1 drugs show new benefits for heart, fertility, cancer and reveal emerging risks
10 articles · Updated · South Florida Sun Sentinel · Apr 26
Recent studies highlight GLP-1 drugs reducing major cardiovascular events by 20% in over 17,000 patients and improving fertility, liver disease, and cancer risk, while new pill formulations reach pharmacies.
Doctors report additional benefits such as reduced inflammation, sleep apnea, and addiction, but also note side effects including hair loss, muscle and bone loss, excess skin, vision changes, and gallbladder disease.
Experts recommend gradual weight loss and medical monitoring to minimize risks, as research expands into GLP-1 effects on Alzheimer's, mental health, and reproductive outcomes, reflecting the drugs' growing impact beyond diabetes and obesity.
How can doctors balance the potent cancer-risk reduction of GLP-1s against their newly discovered dangers?
If stopping GLP-1s reverses their heart benefits, are patients facing a lifelong dependency?
Can genetic testing soon predict who will thrive on GLP-1s and who will face severe side effects?
As GLP-1s cause muscle and bone loss, what is the hidden cost of this revolutionary weight loss?
With risks of 'Ozempic mouth' and gallbladder disease, are the cascading side effects worth the benefits?
Are we trading food addiction for emotional apathy by rewiring the brain's reward system with GLP-1s?
Semaglutide and GLP-1 Receptor Agonists: A 20% Cardiovascular Risk Reduction and Multifaceted Benefits in Obesity and Metabolic Disease
Overview
The SELECT trial (2023-2025) revealed that semaglutide reduces major cardiovascular events by 20% in non-diabetic adults with cardiovascular disease and obesity, leading to its approval as the first GLP-1 receptor agonist for cardiovascular risk reduction in this group. Semaglutide's benefits arise from direct vascular protection, anti-inflammatory effects, and metabolic improvements beyond weight loss. It also significantly improves liver health by resolving steatohepatitis and reducing fibrosis, driven by weight loss and better glycemic control. Additionally, GLP-1 receptor agonists lower overall cancer risk, especially for obesity-related cancers, though a potential kidney cancer risk needs further study. However, stopping treatment quickly raises cardiovascular risk, and side effects often cause discontinuation. Despite strong guideline endorsements, high costs and access barriers limit widespread use.